Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Long-term follow up of 3 T MRI-detected brain lesions after percutaneous catheter-based left atrial appendage closure.

Bellmann B, Rillig A, Skurk C, Leistner DM, Haeusler KG, Lin T, Geran R, Koehler L, Guttmann S, Tscholl V, Roser M, Lenz K, Villringer K, Wun Park J, Fiebach JB, Landmesser U.

Catheter Cardiovasc Interv. 2018 Aug 1;92(2):327-333. doi: 10.1002/ccd.27611. Epub 2018 May 8.

PMID:
29737618
2.

Left atrial appendage angiography is associated with the incidence and number of magnetic resonance imaging-detected brain lesions after percutaneous catheter-based left atrial appendage closure.

Rillig A, Bellmann B, Skurk C, Leistner DM, Haeusler KG, Lin T, Geran R, Koehler L, Guttmann S, Steffens D, Kasner M, Jakob P, Tscholl V, Roser M, Lenz K, Villringer K, Park JW, Fiebach JB, Landmesser U.

Heart Rhythm. 2018 Jan;15(1):3-8. doi: 10.1016/j.hrthm.2017.11.015.

PMID:
29304951
3.

Olfactory dysfunction in patients with primary progressive MS.

Schmidt FA, Maas MB, Geran R, Schmidt C, Kunte H, Ruprecht K, Paul F, Göktas Ö, Harms L.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 14;4(4):e369. doi: 10.1212/NXI.0000000000000369. eCollection 2017 Jul.

4.

A prospective long-term study on the effects of rapid maxillary expansion in the early mixed dentition.

Geran RG, McNamara JA Jr, Baccetti T, Franchi L, Shapiro LM.

Am J Orthod Dentofacial Orthop. 2006 May;129(5):631-40.

PMID:
16679203
5.

The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review.

Goldin A, Venditti JM, Geran R.

Invest New Drugs. 1985;3(1):3-21. Review.

PMID:
3886588
6.

Use of a Lactobacillus casei assay as a prescreen for potential anticancer agents: an update study.

Otani TT, Briley MR, Geran RI.

J Pharm Sci. 1984 Feb;73(2):264-5.

PMID:
6423806
7.

Potential CNS antitumor agents VI: aziridinylbenzoquinones III.

Driscoll JS, Dudeck L, Congleton G, Geran RI.

J Pharm Sci. 1979 Feb;68(2):185-8.

PMID:
423089
9.

Characterization and responsiveness of the Madison 109 lung carcinoma to various antitumor agents.

Marks TA, Woodman RJ, Geran RI, Billups LH, Madison RM.

Cancer Treat Rep. 1977 Nov;61(8):1459-70.

PMID:
922751
10.

A statistical-heuristic methods for automated selection of drugs for screening.

Hodes L, Hazard GF, Geran RI, Richman S.

J Med Chem. 1977 Apr;20(4):469-75.

PMID:
850232
11.

Modified protocol for the testing of new synthetics in the L1210 lymphoid leukemia murine model in the DR&D program, DCT, NCI.

Geran RI, Greenberg NH, Macdonald MM, Abbott BJ.

Natl Cancer Inst Monogr. 1977 Mar;(45):151-3. No abstract available.

PMID:
927490
12.

DON, CONV and DONV-III. Pharmacologic and toxicologic studies.

Cooney DA, Jayaram HN, Milman HA, Homan ER, Pittillo R, Geran RI, Ryan J, Rosenbluth RJ.

Biochem Pharmacol. 1976 Aug 15;25(16):1859-70. No abstract available.

PMID:
9092
13.

Review of selected experimental brain tumor models used in chemotherapy experiments.

Merker PC, Wodinsky I, Geran RI.

Cancer Chemother Rep. 1975 Jul-Aug;59(4):729-36. No abstract available.

PMID:
1175167
15.

A mouse ependymoblastoma as an experimental model for screening potential antineoplastic drugs.

Geran RI, Congleton GF, Dudeck LE, Abbott BJ, Gargus JL.

Cancer Chemother Rep 2. 1974 Dec;4(4):53-87. No abstract available.

PMID:
4447935

Supplemental Content

Support Center